5-[(4-[1,1'-Biphenyl]-4-yl-1,6-dihydro-6-oxo-2-pyrimidinyl)thio]-N-hydroxypentanamide

MC 1742 is a novel histone deacetylase inhibitor, which has been shown to induce growth arrest, apoptosis and differentiation in sarcoma cancer stem cells.

MC1742 is a uracil-based hydroxyamide (UBHA) th at acts as a subtype-selective histone deacetylases (HDACs) inhibitor (IC50: class I HDAC1/2/3/8 = 100/110/20/610 nM, class IIB HDAC6/10 = 7/40 nM, class IV HDAC11 = 100 nM, class IIA HDAC4/5/7/9 >50 μM). MC1742 exerts greater antiproliferation potency than SAHA in sarcoma cancer stem cell (CSC) cultures (MC1742/SAHA IC50 in μM = 0.25/1/RD, 1.12/1.13//MG-63, 1.4/3.92/SK-ES-1 post 72-hr treatment) and effectively reactivates HIV from latency (EC50 = 350 nM; JL at 10.6 cells) by upregulating histone acetylation at the HIV promoter without activating T cells.

Store at -20°C